MediciNova

MNOV

Market cap $76.8M

1.56 USD

+0.17

12.23%

At close Updated Mar 20, 4:00 PM EDT

Pre-market

After hours

1.53

-0.03

1.92%

1 day

12.23%

5 days

6.85%

1 month

3 months

12.23%

6 months

21.88%

Year to date

17.29%

1 year

3.31%

5 years

-72.24%

10 years

-73.42%

About: MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Employees: 6

Healthcare Biotechnology